中国临床药理学杂志2017，Vol.33Issue(21)：2124-2126,2142,4.DOI:10.13699/j.cnki.1001-6821.2017.21.010
参麦注射液对胸外科手术患者预后的临床疗效与安全性
Clinical effect and safety of Shenmai injection on the prognosis of thoracic surgery patients
摘要
Abstract
Objective To study the clinical effect and safety of Shenmai injection on the prognosis of thoracic surgery patients.Methods A total of 48 patients with thoracic surgery were randomly divided into control group and treatment group with 24 cases per group.Conventional perioperative treatment was taken for both of them.While the treatment group had additional application of Shenmai injection,which was given by intravenous infusion,50 mL,qd,after anesthesia induction,and was continuously used for 5 d.The serum levels of interleukin-6 (IL-6),IL-8,complement C3,complement C4,immunologic function,and adverse drug reactions at the time of preoperative and postoperative 1,4,48,120 h were compared between two groups.Results After operative 1,4,48,120 h,the levels of IL-6 in treatment group were (124.58 ±29.12),(90.26 ± 15.83),(29.17 ±4.21) and (16.53 ± 2.02) pg · mL-1;while in the control group were (398.56 ± 56.22),(239.68 ± 34.23),(148.52 ± 18.93) and (96.43 ± 14.63) pg · mL-1.The level of IL-8 in treatment group were (16.19±5.24),(9.26±3.13),(4.38 ±1.42) and (3.43 ±1.14) pg· mL-1;while IL-8 of the control group were (24.57 ± 6.33),(19.79 ± 3.17),(148.52 ± 18.92) and (96.4 ± 14.63) pg · mL-1.The differences of The IL-6 and IL-8 in the two groups at each time point after the operation were statistically significant (all P ＜0.05).At the time of before operative and after perative 1,4,48,120 h,the level of complement C3 in the treatment group were (1.12 ± 0.47)％,(0.85 ± 0.22)％,(0.80 ± 0.26)％,(0.78 ±0.19)％ and (0.77 ±0.14)％;while in control group were (1.10 ± 0.47)％,(0.61 ± 0.28)％,(0.76±0.24)％,(0.83 ±0.21)％ and (0.81 ±0.16)％.The level of C4 in the treatment group were (0.49 ±0.27)％,(0.31 ±0.16)％,(0.35 ±0.14)％,(0.36 ±0.17)％ and (0.35 ±0.15)％;while in the control group were (0.51 ±0.28)％,(0.37 ±0.21)％,(0.32 ±0.18)％,(0.39 ±0.14)％ and (0.37 ±0.16)％.Compared with after operative levet,the differences of C3 and C4 level in the two groups at each time point of postoperative were statistically significant (all P ＜ 0.05).At the time of before operative and after operative 1,4,48,120 h.The level of CD3+ in treatment group were (69.87 ± 2.34)％,(60.49 ± 2.18)％,(54.17 ± 1.78)％,(52.46 ± 1.79)％ and (51.41 ± 1.79)％;while in the control group were (70.12 ±2.47)％,(53.18 ±2.19)％,(52.52 ± 1.79) ％,(50.79 ± 2.09) ％ and (50.31 ± 1.72) ％.The level of CD4 + in the treatment group were (43.04 ±3.85)％,(35.46 ±2.56)％,(32.17 ± 1.98)％,(29.59 ±2.14)％ and (29.21 ±2.11)％;while in the control group were (42.93 ±2.51)％,(32.73 ±2.28)％,(30.41 ±2.04)％,(31.14 ± 1.89)％ and (30.57 ±2.16) ％.CD4+/CD8 + in the treatment group were (1.57 ± 0.39),(1.40 ± 0.41),(1.39 ± 0.37),(1.37±0.35) and (1.38±0.36),while in the control group,they were (1.56 ±0.43),(1.24 ±0.29),(1.33 ± 0.25),(1.36 ± 0.28) and (1.39 ± 0.34).Compared with postoperative level,the differences of CD3+,CD4+,CD4+/CD8+ level in the two groups at each time point of postoperative were statistically significant (all P ＜ 0.05).Both of the two groups had no severe adverse drug reactions in the study.Conclusion Shenmai injection can significantly improve the therapeutic effect of the patients with thoracic surgery,which can improve the patient's immune function and reduce patients level of inflammatory cytokines and complement C3 and C4,without increasing the incidence of adverse drug reactions.关键词
参麦注射液/胸外科手术/补体水平/免疫功能/炎症因子Key words
Shenmai injection/thoracic surgery/complement level/immune function/inflammatory factor分类
医药卫生引用本文复制引用
周成伟,赵伟军,徐芬,赵晓东..参麦注射液对胸外科手术患者预后的临床疗效与安全性[J].中国临床药理学杂志,2017,33(21):2124-2126,2142,4.基金项目
浙江省医学会临床科研基金资助项目(2013ZYC-A75) （2013ZYC-A75）
